MXDHF - MDxHealth SA

Other OTC - Other OTC Delayed Price. Currency in USD

MDxHealth SA

CAP Business Center
Rue d'Abhooz, 31
Herstal 4040
Belgium
32 4 257 70 21
http://www.mdxhealth.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees232

Key Executives

NameTitlePayExercisedYear Born
Dr. Jan GroenCEO, MD, Pres & Exec. Director566.9kN/A1960
Mr. Jean-Marc RoelandtCFO & Exec. VPN/AN/A1965
Dr. Wim Van CriekingeChief Scientific OfficerN/AN/A1972
Mr. Joseph SolleeChief Compliance Officer, Exec. VP of Corp. Devel. & Gen. CounselN/AN/A1965
Mr. Paul MarrExec. VP of Sales for North AmericaN/AN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

MDxHealth SA operates as a molecular diagnostics company in Germany, the Netherlands, Poland, the United States, rest of European Union, and internationally. The company develops and commercializes epigenetic and other molecular tests for cancer assessment and the personalized treatment of patients. Its tests are based on genetic, epigenetic (methylation) and other molecular technologies, and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The company's product pipeline includes tests for prostate, bladder, kidney, cervical, and brain cancers. Its products include ConfirmMDx, a tissue-based epigenetic test for prostate cancer; SelectMDx, a urine-based mRNA test for prostate cancer; and AssureMDx bladder cancer detection test for patients with unresolved hematuria. The company's preclinical development products comprise InformMDx, a tissue-based gene expression panel for prostate cancer; SelectMDx assay to a point of care testing platform; and MonitorMDx, a blood-based test for prostate cancer. It has collaboration agreement with 3D Signatures Inc. to evaluate prognostic test candidate for prostate cancer. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was founded in 2003 and is headquartered in Herstal, Belgium.

Corporate Governance

MDxHealth SA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.